Triad pyrazole–thiazole–coumarin heterocyclic core effectively inhibit HSP and drive cancer cells to apoptosis

References

• Abulkhair, H. S., Turky, A., Ghiaty, A., Ahmed, H. E., & Bayoumi, A. H. (2020). Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies. Bioorganic Chemistry, 100, 103899. https://doi.org/10.1016/j.bioorg.2020.103899
   PubMed Web of Science ®Google Scholar
• Bansal, Y., Sethi, P., & Bansal, G. (2013). Coumarin: A potential nucleus for anti-inflammatory molecules. Medicinal Chemistry Research, 22(7), 3049–3060. https://doi.org/10.1007/s00044-012-0321-6
   Web of Science ®Google Scholar
• Benazzouz-Touami, A., Chouh, A., Halit, S., Terrachet-Bouaziz, S., Makhloufi-Chebli, M., Ighil-Ahriz, K., & Silva, A. M. (2022). New coumarin-pyrazole hybrids: Synthesis, docking studies and biological evaluation as potential cholinesterase inhibitors. Journal of Molecular Structure, 1249, 131591. https://doi.org/10.1016/j.molstruc.2021.131591
   Web of Science ®Google Scholar
• Chen, W., Jiang, J., Wang, P. P., Gong, L., Chen, J., Du, W., Bi, K., & Diao, H. (2019). Identifying hepatocellular carcinoma driver genes by integrative pathway crosstalk and protein interaction network. DNA and Cell Biology, 38(10), 1112–1124. https://doi.org/10.1089/dna.2019.4869
   PubMed Web of Science ®Google Scholar
• Coşkun, K. A., Koca, İ., Gümüş, M., & Tutar, Y. (2021). Designing specific HSP70 substrate binding domain inhibitor for perturbing protein folding pathways to inhibit cancer mechanism. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 21(11), 1472–1480.
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(42), 42717. https://doi.org/10.1038/srep42717
   PubMedGoogle Scholar
• De Luca, A., Maiello, M. R., D'Alessio, A., Pergameno, M., & Normanno, N. (2012). The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opinion on Therapeutic Targets, 16(sup2), S17–S27. https://doi.org/10.1517/14728222.2011.639361
   PubMed Web of Science ®Google Scholar
• Delire, B., & Stärkel, P. (2015). The Ras/MAPK pathway and hepatocarcinoma: Pathogenesis and therapeutic implications. European Journal of Clinical Investigation, 45(6), 609–623. https://doi.org/10.1111/eci.12441
   PubMed Web of Science ®Google Scholar
• Dennington, R., Keith, T., & Millam, J. (2009). GaussView, version 5. Semichem Inc.
   Google Scholar
• Dérijard, B., Raingeaud, J., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J., & Davis, R. J. (1995). Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science (New York, N.Y.), 267(5198), 682–685. https://doi.org/10.1126/science.7839144
   PubMed Web of Science ®Google Scholar
• Dorababu, A. (2021). Coumarin-heterocycle framework: A privileged approach in promising anticancer drug design. European Journal of Medicinal Chemistry Reports, 2, 100006. https://doi.org/10.1016/j.ejmcr.2021.100006
   Google Scholar
• Duckett, C. S., Li, F., Wang, Y., Tomaselli, K. J., Thompson, C. B., & Armstrong, R. C. (1998). Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome c. Molecular and Cellular Biology, 18(1), 608–615. https://doi.org/10.1128/MCB.18.1.608
   PubMed Web of Science ®Google Scholar
• Elkaeed, E. B., Yousef, R. G., Elkady, H., Gobaara, I. M., Alsfouk, A. A., Husein, D. Z., Ibrahim, I. M., Metwaly, A. M., & Eissa, I. H. (2022). The assessment of anticancer and VEGFR-2 ınhibitory activities of a new 1 H-ındole derivative: In silico and ın vitro approaches. Processes, 10(7), 1391. https://doi.org/10.3390/pr10071391
   Web of Science ®Google Scholar
• El-Shershaby, M. H., El-Gamal, K. M., Bayoumi, A. H., El-Adl, K., Alswah, M., Ahmed, H. E., Al-Karmalamy, A. A., & Abulkhair, H. S. (2021). The antimicrobial potential and pharmacokinetic profiles of novel quinoline-based scaffolds: Synthesis and in silico mechanistic studies as dual DNA gyrase and DHFR inhibitors. New Journal of Chemistry, 45(31), 13986–14004. https://doi.org/10.1039/D1NJ02838C
   Web of Science ®Google Scholar
• Emami, S., & Dadashpour, S. (2015). Current developments of coumarin-based anti-cancer agents in medicinal chemistry. European Journal of Medicinal Chemistry, 102, 611–630. https://doi.org/10.1016/j.ejmech.2015.08.033
   PubMed Web of Science ®Google Scholar
• Fang, J., Dagenais, S. L., Erickson, R. P., Arlt, M. F., Glynn, M. W., Gorski, J. L., Seaver, L. H., & Glover, T. W. (2000). Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. The American Journal of Human Genetics, 67(6), 1382–1388. https://doi.org/10.1086/316915
   PubMed Web of Science ®Google Scholar
• Feng, D., Zhang, A., Yang, Y., & Yang, P. (2020). Coumarin‐containing hybrids and their antibacterial activities. Archiv der Pharmazie, 353(6), 1900380. https://doi.org/10.1002/ardp.201900380
   Web of Science ®Google Scholar
• Florkiewicz, R., Shibata, F., Barankiewicz, T., Baird, A., Gonzalez, A. M., Florkiewicz, E., & Shah, N. (1991). Basic fibroblast growth factor gene expression. Annals of the New York Academy of Sciences, 638(1), 109–126. https://doi.org/10.1111/j.1749-6632.1991.tb49022.x
   PubMedGoogle Scholar
• Frisch, M. J., Trucks, G., Schlegel, H., Scuseria, G., Robb, M., Cheeseman, J., Scalmani, G., Barone, V., Mennucci, B., & Petersson, G. (2009). Gaussian 09, Revision D. 01. Gaussian. Inc.
   Google Scholar
• Ghate, M., Kusanur, R., & Kulkarni, M. (2005). Synthesis and in vivo analgesic and anti-inflammatory activity of some bi heterocyclic coumarin derivatives. European Journal of Medicinal Chemistry, 40(9), 882–887.
   PubMed Web of Science ®Google Scholar
• Gümüş, M., Dişli, A., Yakan, M., Yiğitcan, S., & Koca, İ. (2018). One-pot and multi-step syntheses of new 2-(4, 5-dihydro-1H-pyrazol-1-yl) thiazole derivatives. Organic Communications, 11(2), 98–110. https://doi.org/10.25135/acg.oc.40.18.03.071
   Web of Science ®Google Scholar
• Gümüş, M. (2016). The elucidation of the structure and the synthesis of the binary heterocyclic compounds containing thiazole ring and expected to show anticancer activity. PhD, Gazi University, Türkiye. https://tez.yok.gov.tr/UlusalTezMerkezi/tezSorguSonucYeni.jsp.
   Google Scholar
• Hannak, E., Kirkham, M., Hyman, A. A., & Oegema, K. (2001). Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans. Journal of Cell Biology, 155(7), 1109–1116. https://doi.org/10.1083/jcb.200108051
   PubMed Web of Science ®Google Scholar
• Dassault Systèmes BIOVIA. (2017). Discovery Studio Modeling Environment, Release 2017. Dassault Systèmes; San Diego, CA, USA.
   Google Scholar
• Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., & Bourne P.E. (2000). The Protein Data Bank. Nucleic Acids Research, 28, 235-242. https://doi.org/10.1093/nar/28.1.235
   Google Scholar
• Keri, R. S., Sasidhar, B., Nagaraja, B. M., & Santos, M. A. (2015). Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents. European Journal of Medicinal Chemistry, 100, 257–269. https://doi.org/10.1016/j.ejmech.2015.06.017
   PubMed Web of Science ®Google Scholar
• King, D., Yeomanson, D., & Bryant, H. E. (2015). PI3King the lock: Targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. Journal of Pediatric Hematology/Oncology, 37(4), 245–251. https://doi.org/10.1097/MPH.0000000000000329
   PubMed Web of Science ®Google Scholar
• Koca, I., Gumus, M., Ozgur, A., Disli, A., & Tutar, Y. (2015). A novel approach to inhibit heat shock response as anticancer strategy by coumarine compounds containing thiazole skeleton. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 15(7), 916–930.
   PubMed Web of Science ®Google Scholar
• Kreusch, A., Han, S., Brinker, A., Zhou, V., Choi, H-s., He, Y., Lesley, S. A., Caldwell, J., & Gu, X-j. (2005). Crystal structures of human HSP90α-complexed with dihydroxyphenylpyrazoles. Bioorganic & Medicinal Chemistry Letters, 15(5), 1475–1478. https://doi.org/10.1016/j.bmcl.2004.12.087
   PubMed Web of Science ®Google Scholar
• Lazar, C., Kluczyk, A., Kiyota, T., & Konishi, Y. (2004). Drug evolution concept in drug design: 1. Hybridization method. Journal of Medicinal Chemistry, 47(27), 6973–6982.
   PubMed Web of Science ®Google Scholar
• Lee, S., Sivakumar, K., Shin, W.-S., Xie, F., & Wang, Q. (2006). Synthesis and anti-angiogenesis activity of coumarin derivatives. Bioorganic & Medicinal Chemistry Letters, 16(17), 4596–4599. https://doi.org/10.1016/j.bmcl.2006.06.007
   PubMed Web of Science ®Google Scholar
• Lin, J., Jinno, S., & Okayama, H. (2001). Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell’s proliferation competence. Oncogene, 20(16), 2000–2009. https://doi.org/10.1038/sj.onc.1204375
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23(1-3), 3–25. https://doi.org/10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• Liu, X.-H., Liu, H.-F., Chen, J., Yang, Y., Song, B.-A., Bai, L.-S., Liu, J.-X., Zhu, H.-L., & Qi, X.-B. (2010). Synthesis and molecular docking study of novel coumarin derivatives containing 4, 5-dihydropyrazole moiety as potential antitumor agents. Bioorganic & Medicinal Chemistry Letters, 20(19), 5705–5708. https://doi.org/10.1016/j.bmcl.2010.08.017
   PubMed Web of Science ®Google Scholar
• Liu, Y., Yang, H., Guo, Q., Liu, T., Jiang, Y., Zhao, M., Zeng, K., & Tu, P. (2020). Cucurbitacin E inhibits Huh7 hepatoma carcinoma cell proliferation and metastasis via suppressing MAPKs and JAK/STAT3 pathways. Molecules, 25(3), 560. https://doi.org/10.3390/molecules25030560
   PubMed Web of Science ®Google Scholar
• Maik-Rachline, G., Wortzel, I., & Seger, R. (2021). Alternative splicing of MAPKs in the regulation of signaling specificity. Cells, 10(12), 3466. https://doi.org/10.3390/cells10123466
   PubMed Web of Science ®Google Scholar
• Moinul, M., Khatun, S., Amin, S. A., Jha, T., & Gayen, S. (2022). Recent trends in fragment-based anticancer drug design strategies against different targets: A mini-review. Biochemical Pharmacology, 115301.
   Google Scholar
• Munawar, S., Windley, M. J., Tse, E. G., Todd, M. H., Hill, A. P., Vandenberg, J. I., & Jabeen, I. (2018). Experimentally validated pharmacoinformatics approach to predict hERG inhibition potential of new chemical entities. Frontiers in Pharmacology, 9, 1035. https://doi.org/10.3389/fphar.2018.01035
   PubMed Web of Science ®Google Scholar
• Mustafa, Y., Mohammed, E., & Khalil, R. (2021). Synthesis, characterization, and anticoagulant activity of new functionalized biscoumarins. Egyptian Journal of Chemistry, 64(8), 4461–4468.
   Web of Science ®Google Scholar
• Nasab, N. H., Azimian, F., Kruger, H. G., & Kim, S. J. (2022). Acetylcoumarin in cyclic and heterocyclic-containing coumarins: Synthesis and biological applications. Tetrahedron, 129, 133158. https://doi.org/10.1016/j.tet.2022.133158
   Web of Science ®Google Scholar
• Priest, B., Bell, I. M., & Garcia, M. (2008). Role of hERG potassium channel assays in drug development. Channels, 2(2), 87–93. https://doi.org/10.4161/chan.2.2.6004
   PubMed Web of Science ®Google Scholar
• Roy, M.-L., Dumaine, R., & Brown, A. M. (1996). HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation, 94(4), 817–823.
   PubMed Web of Science ®Google Scholar
• Sanguinetti, M. C., & Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature, 440(7083), 463–469. https://doi.org/10.1038/nature04710
   PubMed Web of Science ®Google Scholar
• Sobecki, M., Mrouj, K., Camasses, A., Parisis, N., Nicolas, E., Llères, D., Gerbe, F., Prieto, S., Krasinska, L., David, A., Eguren, M., Birling, M.-C., Urbach, S., Hem, S., Déjardin, J., Malumbres, M., Jay, P., Dulic, V., Lafontaine, D. L., Feil, R., & Fisher, D. (2016). The cell proliferation antigen Ki-67 organises heterochromatin. eLife, 5, e13722. https://doi.org/10.7554/eLife.13722
   PubMed Web of Science ®Google Scholar
• Sousa, S. F., Fernandes, P. A., & Ramos, M. J. (2006). Protein–ligand docking: Current status and future challenges. Proteins: Structure, Function, and Bioinformatics, 65(1), 15–26. https://doi.org/10.1002/prot.21082
   PubMed Web of Science ®Google Scholar
• Taghour, M. S., Elkady, H., Eldehna, W. M., El-Deeb, N. M., Kenawy, A. M., Elkaeed, E. B., Alsfouk, A. A., Alesawy, M. S., Metwaly, A. M., & Eissa, I. H. (2022). Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in-silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 1903–1917. https://doi.org/10.1080/14756366.2022.2085693
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: İmproving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
   PubMed Web of Science ®Google Scholar
• Tutar, Y. (2016). Heat shock protein 90 inhibition in cancer drug discovery: From chemistry to futural clinical applications. Anti-Cancer Agents in Medicinal Chemistry, 16(3), 280–290.
   PubMed Web of Science ®Google Scholar
• Tutar, L., & Tutar, Y. (2008). Ydj1 but not Sis1 stabilizes Hsp70 protein under prolonged stress in vitro. Biopolymers, 89(3), 171–174. https://doi.org/10.1002/bip.20881
   PubMed Web of Science ®Google Scholar
• Tutar, L., & Tutar, Y. (2010). Heat shock proteins; an overview. Current Pharmaceutical Biotechnology, 11(2), 216–222. https://doi.org/10.2174/138920110790909632
   PubMed Web of Science ®Google Scholar
• Velpula, R., Deshineni, R., Gali, R., & Bavantula, R. (2016). One-pot multicomponent synthesis of novel 1-thiazolyl-5-coumarin-3-yl-pyrazole derivatives and evaluation of their cytotoxic activity. Research on Chemical Intermediates, 42(3), 1729–1740. https://doi.org/10.1007/s11164-015-2114-2
   Web of Science ®Google Scholar
• Warmke, J. W., & Ganetzky, B. (1994). A family of potassium channel genes related to eag in Drosophila and mammals. Proceedings of the National Academy of Sciences, 91(8), 3438–3442. https://doi.org/10.1073/pnas.91.8.3438
   PubMed Web of Science ®Google Scholar
• Zhang, H., Wang, Q., Liu, J., & Cao, H. (2018). Inhibition of the PI3K/Akt signaling pathway reverses sorafenib‑derived chemo‑resistance in hepatocellular carcinoma. Oncology Letters, 15(6), 9377–9384.
   PubMed Web of Science ®Google Scholar
• Zhang, L., & Xu, Z. (2019). Coumarin-containing hybrids and their anticancer activities. European Journal of Medicinal Chemistry, 181, 111587. https://doi.org/10.1016/j.ejmech.2019.111587
   PubMed Web of Science ®Google Scholar